Related Experiment Videos
Between Science and Big Business: Tapping Mary Jane's Uncharted Potential
Katharina Grotsch1, Valery V Fokin1
1Bridge Institute and Loker Hydrocarbon Research Institute, University of Southern California, 1002 Childs Way, Los Angeles, California 90089-3502, United States.
ACS Central Science
|March 2, 2022
Summary
Cannabis compounds, including endogenous cannabinoids, are crucial for homeostasis and disease treatment. Further research and innovation are needed to overcome drug discovery challenges and address industry disconnects.
Area of Science:
- Pharmacology
- Neuroscience
- Drug Discovery
Background:
- Cannabis has a long history but limited scientific data on its physiological effects.
- The endogenous cannabinoid system is vital for homeostasis and a therapeutic target for diseases.
Purpose of the Study:
- To summarize current knowledge on endogenous and plant-based cannabinoids.
- To address challenges in cannabinoid drug discovery.
- To propose strategies for utilizing cannabinoid polypharmacology in complex diseases.
Main Methods:
- Literature review and synthesis of existing research on cannabinoids.
- Analysis of current drug discovery issues and industry dynamics.
- Proposal for integrating scientific, technological, and historical data.
Main Results:
- Identified a significant gap in replicable data on cannabis constituents and their physiological impact.
- Highlighted the potential of the endogenous cannabinoid system for therapeutic intervention.
- Pointed out the disconnect between scientific, regulatory, and corporate sectors in the cannabis industry.
Conclusions:
- Emphasized the need for innovative approaches to cannabinoid drug discovery by combining modern science with empirical data.
- Advocated for leveraging the polypharmacological profile of cannabinoids to treat complex diseases.
- Called for greater alignment among scientific, regulatory, and corporate entities to foster industry growth and innovation.